First-in-human optogenetic therapy partially restores light sensitivity in blind patients

A first-in-human optogenetic therapy partially restores light sensitivity in blind patients, Kenya confirms its first Ebola case, and the FDA approves tucatinib for HER2-positive breast cancer maintenance.